Baidu
map

CLIN CANCER RES:AKT抑制剂MK-2206联合阿那曲唑治疗Ⅱ/Ⅲ期PIK3CA突变ER阳性和HER-2阴性乳腺癌

2017-11-18 MedSci MedSci原创

ER受体阳性乳腺癌中AKT高度活化且与内分泌耐药有关。在临床前研究中AKT抑制剂MK-2206可以在雌激素剥夺情况下诱导PIK3CA突变ER阳性乳腺癌凋亡。CLIN CANCER RES近期发表了一篇文章,研究阿那曲唑联合MK-2206是否可以诱导PIK3CA突变ER阳性乳腺癌出现病理完全缓解(pCR)。

ER受体阳性乳腺癌中AKT高度活化且与内分泌耐药有关。在临床前研究中AKT抑制剂MK-2206可以在雌激素剥夺情况下诱导PIK3CA突变ER阳性乳腺癌凋亡。CLIN CANCER RES近期发表了一篇文章,研究阿那曲唑联合MK-2206是否可以诱导PIK3CA突变ER阳性乳腺癌出现病理完全缓解(pCR)。

Ⅱ/Ⅲ期ER阳性/HER-2阴性乳腺癌患者进行预注册并在cycle0接受阿那曲唑治疗28天,期间进行PIK3CA测序。肿瘤PIK3CA突变阳性的患者在cycle1 day2(C1D2)开始MK-2206治疗(每周150mg口服,同时预防性使用泼尼松),在手术前最多接受4周期28天的联合治疗。在预注册,C1D1和C1D17收集标本。最终51例患者进行预注册,22例PIK3CA突变的患者中的16位接受研究药物治疗。3例患者由于C1D17 Ki67>10%(n=2)和毒性反应(n=1)退出研究。13例患者完成新辅助治疗后进行手术。未观察到pCR。皮疹常见。MK-2206并未抑制细胞增殖且在C1D17标本中未诱导细胞凋亡。尽管AKT磷酸化降低,MK-2206治疗后C1D17 PRAS40磷酸化仍然存在。1例患者在手术时出现ESR1突变。

文章最后认为,在PIK3CA突变ER阳性乳腺癌中MK-2206不会增加阿那曲唑疗效,不应进行更大样本量的进一步研究。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (13)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2047970, encodeId=5b5d204e9707f, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Sun Mar 25 23:49:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710574, encodeId=19131e10574e3, content=<a href='/topic/show?id=4ad0142806f' target=_blank style='color:#2F92EE;'>#PIK3CA突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14280, encryptionId=4ad0142806f, topicName=PIK3CA突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=617b31881621, createdName=ms6323715314570549, createdTime=Sun Feb 04 02:49:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656158, encodeId=4f17165615870, content=<a href='/topic/show?id=f4782246ec' target=_blank style='color:#2F92EE;'>#Akt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2246, encryptionId=f4782246ec, topicName=Akt)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c724776724, createdName=xfpan20, createdTime=Fri Dec 15 22:49:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334414, encodeId=cbbd3344142c, content=新辅要走的路还很长啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibD3KHkWpogYEBFLLhK39cF0geS1c8Z7AcaU6HFrV3tTmVHO1gicfzJX0b9axNXIDufnATKNrja9A/132, createdBy=e9992409610, createdName=Qing~~, createdTime=Fri Jul 27 01:58:47 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851572, encodeId=bb9e18515e2e1, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Sep 10 05:49:00 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007514, encodeId=b114200e51409, content=<a href='/topic/show?id=fe2b142e95c' target=_blank style='color:#2F92EE;'>#PIK3CA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14279, encryptionId=fe2b142e95c, topicName=PIK3CA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sat Jun 02 12:49:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263568, encodeId=6f1d26356891, content=好好好好学习学习天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Thu Nov 23 09:13:48 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263381, encodeId=0d612633815f, content=阿那曲唑治疗乳腺癌, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJUlbw1Mf1vppicGcaWPx1YUOgLgKccao77Rykbx3jiazqzwcyXMdzRIZkhFyBPqknibeuOGhXI1VzVg/0, createdBy=7f162154630, createdName=沙漠浪人, createdTime=Wed Nov 22 17:17:47 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263178, encodeId=271a2631e8da, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KiblTyxD95ExbzUoCVcRuhPibXboL28wicFMTXUhCA0RWCyQZYC5Na3ap7CxjialMkB50VEJ0XToQQTC/0, createdBy=470c1945776, createdName=方舒, createdTime=Tue Nov 21 22:02:19 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412270, encodeId=7b6f14122e015, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97950, encryptionId=e9b69e95040, topicName=阿那曲唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=418d2846303, createdName=jiangfeng5068, createdTime=Mon Nov 20 01:49:00 CST 2017, time=2017-11-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2047970, encodeId=5b5d204e9707f, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Sun Mar 25 23:49:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710574, encodeId=19131e10574e3, content=<a href='/topic/show?id=4ad0142806f' target=_blank style='color:#2F92EE;'>#PIK3CA突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14280, encryptionId=4ad0142806f, topicName=PIK3CA突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=617b31881621, createdName=ms6323715314570549, createdTime=Sun Feb 04 02:49:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656158, encodeId=4f17165615870, content=<a href='/topic/show?id=f4782246ec' target=_blank style='color:#2F92EE;'>#Akt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2246, encryptionId=f4782246ec, topicName=Akt)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c724776724, createdName=xfpan20, createdTime=Fri Dec 15 22:49:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334414, encodeId=cbbd3344142c, content=新辅要走的路还很长啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibD3KHkWpogYEBFLLhK39cF0geS1c8Z7AcaU6HFrV3tTmVHO1gicfzJX0b9axNXIDufnATKNrja9A/132, createdBy=e9992409610, createdName=Qing~~, createdTime=Fri Jul 27 01:58:47 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851572, encodeId=bb9e18515e2e1, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Sep 10 05:49:00 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007514, encodeId=b114200e51409, content=<a href='/topic/show?id=fe2b142e95c' target=_blank style='color:#2F92EE;'>#PIK3CA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14279, encryptionId=fe2b142e95c, topicName=PIK3CA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sat Jun 02 12:49:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263568, encodeId=6f1d26356891, content=好好好好学习学习天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Thu Nov 23 09:13:48 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263381, encodeId=0d612633815f, content=阿那曲唑治疗乳腺癌, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJUlbw1Mf1vppicGcaWPx1YUOgLgKccao77Rykbx3jiazqzwcyXMdzRIZkhFyBPqknibeuOGhXI1VzVg/0, createdBy=7f162154630, createdName=沙漠浪人, createdTime=Wed Nov 22 17:17:47 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263178, encodeId=271a2631e8da, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KiblTyxD95ExbzUoCVcRuhPibXboL28wicFMTXUhCA0RWCyQZYC5Na3ap7CxjialMkB50VEJ0XToQQTC/0, createdBy=470c1945776, createdName=方舒, createdTime=Tue Nov 21 22:02:19 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412270, encodeId=7b6f14122e015, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97950, encryptionId=e9b69e95040, topicName=阿那曲唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=418d2846303, createdName=jiangfeng5068, createdTime=Mon Nov 20 01:49:00 CST 2017, time=2017-11-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2047970, encodeId=5b5d204e9707f, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Sun Mar 25 23:49:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710574, encodeId=19131e10574e3, content=<a href='/topic/show?id=4ad0142806f' target=_blank style='color:#2F92EE;'>#PIK3CA突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14280, encryptionId=4ad0142806f, topicName=PIK3CA突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=617b31881621, createdName=ms6323715314570549, createdTime=Sun Feb 04 02:49:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656158, encodeId=4f17165615870, content=<a href='/topic/show?id=f4782246ec' target=_blank style='color:#2F92EE;'>#Akt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2246, encryptionId=f4782246ec, topicName=Akt)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c724776724, createdName=xfpan20, createdTime=Fri Dec 15 22:49:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334414, encodeId=cbbd3344142c, content=新辅要走的路还很长啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibD3KHkWpogYEBFLLhK39cF0geS1c8Z7AcaU6HFrV3tTmVHO1gicfzJX0b9axNXIDufnATKNrja9A/132, createdBy=e9992409610, createdName=Qing~~, createdTime=Fri Jul 27 01:58:47 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851572, encodeId=bb9e18515e2e1, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Sep 10 05:49:00 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007514, encodeId=b114200e51409, content=<a href='/topic/show?id=fe2b142e95c' target=_blank style='color:#2F92EE;'>#PIK3CA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14279, encryptionId=fe2b142e95c, topicName=PIK3CA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sat Jun 02 12:49:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263568, encodeId=6f1d26356891, content=好好好好学习学习天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Thu Nov 23 09:13:48 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263381, encodeId=0d612633815f, content=阿那曲唑治疗乳腺癌, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJUlbw1Mf1vppicGcaWPx1YUOgLgKccao77Rykbx3jiazqzwcyXMdzRIZkhFyBPqknibeuOGhXI1VzVg/0, createdBy=7f162154630, createdName=沙漠浪人, createdTime=Wed Nov 22 17:17:47 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263178, encodeId=271a2631e8da, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KiblTyxD95ExbzUoCVcRuhPibXboL28wicFMTXUhCA0RWCyQZYC5Na3ap7CxjialMkB50VEJ0XToQQTC/0, createdBy=470c1945776, createdName=方舒, createdTime=Tue Nov 21 22:02:19 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412270, encodeId=7b6f14122e015, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97950, encryptionId=e9b69e95040, topicName=阿那曲唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=418d2846303, createdName=jiangfeng5068, createdTime=Mon Nov 20 01:49:00 CST 2017, time=2017-11-20, status=1, ipAttribution=)]
    2017-12-15 xfpan20
  4. [GetPortalCommentsPageByObjectIdResponse(id=2047970, encodeId=5b5d204e9707f, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Sun Mar 25 23:49:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710574, encodeId=19131e10574e3, content=<a href='/topic/show?id=4ad0142806f' target=_blank style='color:#2F92EE;'>#PIK3CA突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14280, encryptionId=4ad0142806f, topicName=PIK3CA突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=617b31881621, createdName=ms6323715314570549, createdTime=Sun Feb 04 02:49:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656158, encodeId=4f17165615870, content=<a href='/topic/show?id=f4782246ec' target=_blank style='color:#2F92EE;'>#Akt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2246, encryptionId=f4782246ec, topicName=Akt)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c724776724, createdName=xfpan20, createdTime=Fri Dec 15 22:49:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334414, encodeId=cbbd3344142c, content=新辅要走的路还很长啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibD3KHkWpogYEBFLLhK39cF0geS1c8Z7AcaU6HFrV3tTmVHO1gicfzJX0b9axNXIDufnATKNrja9A/132, createdBy=e9992409610, createdName=Qing~~, createdTime=Fri Jul 27 01:58:47 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851572, encodeId=bb9e18515e2e1, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Sep 10 05:49:00 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007514, encodeId=b114200e51409, content=<a href='/topic/show?id=fe2b142e95c' target=_blank style='color:#2F92EE;'>#PIK3CA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14279, encryptionId=fe2b142e95c, topicName=PIK3CA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sat Jun 02 12:49:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263568, encodeId=6f1d26356891, content=好好好好学习学习天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Thu Nov 23 09:13:48 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263381, encodeId=0d612633815f, content=阿那曲唑治疗乳腺癌, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJUlbw1Mf1vppicGcaWPx1YUOgLgKccao77Rykbx3jiazqzwcyXMdzRIZkhFyBPqknibeuOGhXI1VzVg/0, createdBy=7f162154630, createdName=沙漠浪人, createdTime=Wed Nov 22 17:17:47 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263178, encodeId=271a2631e8da, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KiblTyxD95ExbzUoCVcRuhPibXboL28wicFMTXUhCA0RWCyQZYC5Na3ap7CxjialMkB50VEJ0XToQQTC/0, createdBy=470c1945776, createdName=方舒, createdTime=Tue Nov 21 22:02:19 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412270, encodeId=7b6f14122e015, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97950, encryptionId=e9b69e95040, topicName=阿那曲唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=418d2846303, createdName=jiangfeng5068, createdTime=Mon Nov 20 01:49:00 CST 2017, time=2017-11-20, status=1, ipAttribution=)]
    2018-07-27 Qing~~

    新辅要走的路还很长啊!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2047970, encodeId=5b5d204e9707f, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Sun Mar 25 23:49:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710574, encodeId=19131e10574e3, content=<a href='/topic/show?id=4ad0142806f' target=_blank style='color:#2F92EE;'>#PIK3CA突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14280, encryptionId=4ad0142806f, topicName=PIK3CA突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=617b31881621, createdName=ms6323715314570549, createdTime=Sun Feb 04 02:49:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656158, encodeId=4f17165615870, content=<a href='/topic/show?id=f4782246ec' target=_blank style='color:#2F92EE;'>#Akt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2246, encryptionId=f4782246ec, topicName=Akt)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c724776724, createdName=xfpan20, createdTime=Fri Dec 15 22:49:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334414, encodeId=cbbd3344142c, content=新辅要走的路还很长啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibD3KHkWpogYEBFLLhK39cF0geS1c8Z7AcaU6HFrV3tTmVHO1gicfzJX0b9axNXIDufnATKNrja9A/132, createdBy=e9992409610, createdName=Qing~~, createdTime=Fri Jul 27 01:58:47 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851572, encodeId=bb9e18515e2e1, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Sep 10 05:49:00 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007514, encodeId=b114200e51409, content=<a href='/topic/show?id=fe2b142e95c' target=_blank style='color:#2F92EE;'>#PIK3CA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14279, encryptionId=fe2b142e95c, topicName=PIK3CA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sat Jun 02 12:49:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263568, encodeId=6f1d26356891, content=好好好好学习学习天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Thu Nov 23 09:13:48 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263381, encodeId=0d612633815f, content=阿那曲唑治疗乳腺癌, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJUlbw1Mf1vppicGcaWPx1YUOgLgKccao77Rykbx3jiazqzwcyXMdzRIZkhFyBPqknibeuOGhXI1VzVg/0, createdBy=7f162154630, createdName=沙漠浪人, createdTime=Wed Nov 22 17:17:47 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263178, encodeId=271a2631e8da, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KiblTyxD95ExbzUoCVcRuhPibXboL28wicFMTXUhCA0RWCyQZYC5Na3ap7CxjialMkB50VEJ0XToQQTC/0, createdBy=470c1945776, createdName=方舒, createdTime=Tue Nov 21 22:02:19 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412270, encodeId=7b6f14122e015, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97950, encryptionId=e9b69e95040, topicName=阿那曲唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=418d2846303, createdName=jiangfeng5068, createdTime=Mon Nov 20 01:49:00 CST 2017, time=2017-11-20, status=1, ipAttribution=)]
    2018-09-10 jklm09
  6. [GetPortalCommentsPageByObjectIdResponse(id=2047970, encodeId=5b5d204e9707f, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Sun Mar 25 23:49:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710574, encodeId=19131e10574e3, content=<a href='/topic/show?id=4ad0142806f' target=_blank style='color:#2F92EE;'>#PIK3CA突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14280, encryptionId=4ad0142806f, topicName=PIK3CA突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=617b31881621, createdName=ms6323715314570549, createdTime=Sun Feb 04 02:49:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656158, encodeId=4f17165615870, content=<a href='/topic/show?id=f4782246ec' target=_blank style='color:#2F92EE;'>#Akt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2246, encryptionId=f4782246ec, topicName=Akt)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c724776724, createdName=xfpan20, createdTime=Fri Dec 15 22:49:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334414, encodeId=cbbd3344142c, content=新辅要走的路还很长啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibD3KHkWpogYEBFLLhK39cF0geS1c8Z7AcaU6HFrV3tTmVHO1gicfzJX0b9axNXIDufnATKNrja9A/132, createdBy=e9992409610, createdName=Qing~~, createdTime=Fri Jul 27 01:58:47 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851572, encodeId=bb9e18515e2e1, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Sep 10 05:49:00 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007514, encodeId=b114200e51409, content=<a href='/topic/show?id=fe2b142e95c' target=_blank style='color:#2F92EE;'>#PIK3CA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14279, encryptionId=fe2b142e95c, topicName=PIK3CA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sat Jun 02 12:49:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263568, encodeId=6f1d26356891, content=好好好好学习学习天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Thu Nov 23 09:13:48 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263381, encodeId=0d612633815f, content=阿那曲唑治疗乳腺癌, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJUlbw1Mf1vppicGcaWPx1YUOgLgKccao77Rykbx3jiazqzwcyXMdzRIZkhFyBPqknibeuOGhXI1VzVg/0, createdBy=7f162154630, createdName=沙漠浪人, createdTime=Wed Nov 22 17:17:47 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263178, encodeId=271a2631e8da, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KiblTyxD95ExbzUoCVcRuhPibXboL28wicFMTXUhCA0RWCyQZYC5Na3ap7CxjialMkB50VEJ0XToQQTC/0, createdBy=470c1945776, createdName=方舒, createdTime=Tue Nov 21 22:02:19 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412270, encodeId=7b6f14122e015, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97950, encryptionId=e9b69e95040, topicName=阿那曲唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=418d2846303, createdName=jiangfeng5068, createdTime=Mon Nov 20 01:49:00 CST 2017, time=2017-11-20, status=1, ipAttribution=)]
    2018-06-02 xinmeili
  7. [GetPortalCommentsPageByObjectIdResponse(id=2047970, encodeId=5b5d204e9707f, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Sun Mar 25 23:49:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710574, encodeId=19131e10574e3, content=<a href='/topic/show?id=4ad0142806f' target=_blank style='color:#2F92EE;'>#PIK3CA突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14280, encryptionId=4ad0142806f, topicName=PIK3CA突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=617b31881621, createdName=ms6323715314570549, createdTime=Sun Feb 04 02:49:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656158, encodeId=4f17165615870, content=<a href='/topic/show?id=f4782246ec' target=_blank style='color:#2F92EE;'>#Akt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2246, encryptionId=f4782246ec, topicName=Akt)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c724776724, createdName=xfpan20, createdTime=Fri Dec 15 22:49:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334414, encodeId=cbbd3344142c, content=新辅要走的路还很长啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibD3KHkWpogYEBFLLhK39cF0geS1c8Z7AcaU6HFrV3tTmVHO1gicfzJX0b9axNXIDufnATKNrja9A/132, createdBy=e9992409610, createdName=Qing~~, createdTime=Fri Jul 27 01:58:47 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851572, encodeId=bb9e18515e2e1, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Sep 10 05:49:00 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007514, encodeId=b114200e51409, content=<a href='/topic/show?id=fe2b142e95c' target=_blank style='color:#2F92EE;'>#PIK3CA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14279, encryptionId=fe2b142e95c, topicName=PIK3CA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sat Jun 02 12:49:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263568, encodeId=6f1d26356891, content=好好好好学习学习天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Thu Nov 23 09:13:48 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263381, encodeId=0d612633815f, content=阿那曲唑治疗乳腺癌, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJUlbw1Mf1vppicGcaWPx1YUOgLgKccao77Rykbx3jiazqzwcyXMdzRIZkhFyBPqknibeuOGhXI1VzVg/0, createdBy=7f162154630, createdName=沙漠浪人, createdTime=Wed Nov 22 17:17:47 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263178, encodeId=271a2631e8da, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KiblTyxD95ExbzUoCVcRuhPibXboL28wicFMTXUhCA0RWCyQZYC5Na3ap7CxjialMkB50VEJ0XToQQTC/0, createdBy=470c1945776, createdName=方舒, createdTime=Tue Nov 21 22:02:19 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412270, encodeId=7b6f14122e015, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97950, encryptionId=e9b69e95040, topicName=阿那曲唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=418d2846303, createdName=jiangfeng5068, createdTime=Mon Nov 20 01:49:00 CST 2017, time=2017-11-20, status=1, ipAttribution=)]
    2017-11-23 zwjnj2

    好好好好学习学习天天向上

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2047970, encodeId=5b5d204e9707f, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Sun Mar 25 23:49:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710574, encodeId=19131e10574e3, content=<a href='/topic/show?id=4ad0142806f' target=_blank style='color:#2F92EE;'>#PIK3CA突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14280, encryptionId=4ad0142806f, topicName=PIK3CA突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=617b31881621, createdName=ms6323715314570549, createdTime=Sun Feb 04 02:49:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656158, encodeId=4f17165615870, content=<a href='/topic/show?id=f4782246ec' target=_blank style='color:#2F92EE;'>#Akt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2246, encryptionId=f4782246ec, topicName=Akt)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c724776724, createdName=xfpan20, createdTime=Fri Dec 15 22:49:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334414, encodeId=cbbd3344142c, content=新辅要走的路还很长啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibD3KHkWpogYEBFLLhK39cF0geS1c8Z7AcaU6HFrV3tTmVHO1gicfzJX0b9axNXIDufnATKNrja9A/132, createdBy=e9992409610, createdName=Qing~~, createdTime=Fri Jul 27 01:58:47 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851572, encodeId=bb9e18515e2e1, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Sep 10 05:49:00 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007514, encodeId=b114200e51409, content=<a href='/topic/show?id=fe2b142e95c' target=_blank style='color:#2F92EE;'>#PIK3CA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14279, encryptionId=fe2b142e95c, topicName=PIK3CA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sat Jun 02 12:49:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263568, encodeId=6f1d26356891, content=好好好好学习学习天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Thu Nov 23 09:13:48 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263381, encodeId=0d612633815f, content=阿那曲唑治疗乳腺癌, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJUlbw1Mf1vppicGcaWPx1YUOgLgKccao77Rykbx3jiazqzwcyXMdzRIZkhFyBPqknibeuOGhXI1VzVg/0, createdBy=7f162154630, createdName=沙漠浪人, createdTime=Wed Nov 22 17:17:47 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263178, encodeId=271a2631e8da, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KiblTyxD95ExbzUoCVcRuhPibXboL28wicFMTXUhCA0RWCyQZYC5Na3ap7CxjialMkB50VEJ0XToQQTC/0, createdBy=470c1945776, createdName=方舒, createdTime=Tue Nov 21 22:02:19 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412270, encodeId=7b6f14122e015, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97950, encryptionId=e9b69e95040, topicName=阿那曲唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=418d2846303, createdName=jiangfeng5068, createdTime=Mon Nov 20 01:49:00 CST 2017, time=2017-11-20, status=1, ipAttribution=)]
    2017-11-22 沙漠浪人

    阿那曲唑治疗乳腺癌

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2047970, encodeId=5b5d204e9707f, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Sun Mar 25 23:49:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710574, encodeId=19131e10574e3, content=<a href='/topic/show?id=4ad0142806f' target=_blank style='color:#2F92EE;'>#PIK3CA突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14280, encryptionId=4ad0142806f, topicName=PIK3CA突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=617b31881621, createdName=ms6323715314570549, createdTime=Sun Feb 04 02:49:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656158, encodeId=4f17165615870, content=<a href='/topic/show?id=f4782246ec' target=_blank style='color:#2F92EE;'>#Akt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2246, encryptionId=f4782246ec, topicName=Akt)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c724776724, createdName=xfpan20, createdTime=Fri Dec 15 22:49:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334414, encodeId=cbbd3344142c, content=新辅要走的路还很长啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibD3KHkWpogYEBFLLhK39cF0geS1c8Z7AcaU6HFrV3tTmVHO1gicfzJX0b9axNXIDufnATKNrja9A/132, createdBy=e9992409610, createdName=Qing~~, createdTime=Fri Jul 27 01:58:47 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851572, encodeId=bb9e18515e2e1, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Sep 10 05:49:00 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007514, encodeId=b114200e51409, content=<a href='/topic/show?id=fe2b142e95c' target=_blank style='color:#2F92EE;'>#PIK3CA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14279, encryptionId=fe2b142e95c, topicName=PIK3CA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sat Jun 02 12:49:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263568, encodeId=6f1d26356891, content=好好好好学习学习天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Thu Nov 23 09:13:48 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263381, encodeId=0d612633815f, content=阿那曲唑治疗乳腺癌, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJUlbw1Mf1vppicGcaWPx1YUOgLgKccao77Rykbx3jiazqzwcyXMdzRIZkhFyBPqknibeuOGhXI1VzVg/0, createdBy=7f162154630, createdName=沙漠浪人, createdTime=Wed Nov 22 17:17:47 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263178, encodeId=271a2631e8da, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KiblTyxD95ExbzUoCVcRuhPibXboL28wicFMTXUhCA0RWCyQZYC5Na3ap7CxjialMkB50VEJ0XToQQTC/0, createdBy=470c1945776, createdName=方舒, createdTime=Tue Nov 21 22:02:19 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412270, encodeId=7b6f14122e015, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97950, encryptionId=e9b69e95040, topicName=阿那曲唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=418d2846303, createdName=jiangfeng5068, createdTime=Mon Nov 20 01:49:00 CST 2017, time=2017-11-20, status=1, ipAttribution=)]
    2017-11-21 方舒

    学习

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2047970, encodeId=5b5d204e9707f, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Sun Mar 25 23:49:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710574, encodeId=19131e10574e3, content=<a href='/topic/show?id=4ad0142806f' target=_blank style='color:#2F92EE;'>#PIK3CA突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14280, encryptionId=4ad0142806f, topicName=PIK3CA突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=617b31881621, createdName=ms6323715314570549, createdTime=Sun Feb 04 02:49:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656158, encodeId=4f17165615870, content=<a href='/topic/show?id=f4782246ec' target=_blank style='color:#2F92EE;'>#Akt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2246, encryptionId=f4782246ec, topicName=Akt)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c724776724, createdName=xfpan20, createdTime=Fri Dec 15 22:49:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334414, encodeId=cbbd3344142c, content=新辅要走的路还很长啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibD3KHkWpogYEBFLLhK39cF0geS1c8Z7AcaU6HFrV3tTmVHO1gicfzJX0b9axNXIDufnATKNrja9A/132, createdBy=e9992409610, createdName=Qing~~, createdTime=Fri Jul 27 01:58:47 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851572, encodeId=bb9e18515e2e1, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Sep 10 05:49:00 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007514, encodeId=b114200e51409, content=<a href='/topic/show?id=fe2b142e95c' target=_blank style='color:#2F92EE;'>#PIK3CA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14279, encryptionId=fe2b142e95c, topicName=PIK3CA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sat Jun 02 12:49:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263568, encodeId=6f1d26356891, content=好好好好学习学习天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Thu Nov 23 09:13:48 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263381, encodeId=0d612633815f, content=阿那曲唑治疗乳腺癌, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJUlbw1Mf1vppicGcaWPx1YUOgLgKccao77Rykbx3jiazqzwcyXMdzRIZkhFyBPqknibeuOGhXI1VzVg/0, createdBy=7f162154630, createdName=沙漠浪人, createdTime=Wed Nov 22 17:17:47 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263178, encodeId=271a2631e8da, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KiblTyxD95ExbzUoCVcRuhPibXboL28wicFMTXUhCA0RWCyQZYC5Na3ap7CxjialMkB50VEJ0XToQQTC/0, createdBy=470c1945776, createdName=方舒, createdTime=Tue Nov 21 22:02:19 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412270, encodeId=7b6f14122e015, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97950, encryptionId=e9b69e95040, topicName=阿那曲唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=418d2846303, createdName=jiangfeng5068, createdTime=Mon Nov 20 01:49:00 CST 2017, time=2017-11-20, status=1, ipAttribution=)]

相关资讯

Oncotarget :三阴性乳腺癌新突破:科学家首次识别全新治疗靶点

根据一项最新研究显示,研究人员找到了一种对激素治疗无效的致命乳腺癌机制,新的发现有望带来新的疗法和药物的开发。

NCCN临床实践指南:乳腺癌(2017.V3)

2017年11月,美国国家综合癌症网络(NCCN)发布了乳腺癌管理指南2017年第3版,指南主要内容涉及: 指南更新摘要 非浸润性乳腺癌 浸润性乳腺癌 特殊考虑

CSCO 2017:徐兵河教授呼吁对乳腺癌患者进行全程全方位管理

乳腺癌是女性最常见的恶性肿瘤,相对于其他瘤种,乳腺癌患者的预后较好,五年生存期超过70%以上。但在漫长的治疗过程中仍然可能会出现各方面的问题,如何对乳腺癌患者进行全程全方位管理,下面有请中国医学科学院肿瘤医院徐兵河教授谈谈他对这方面的理解。

胡夕春教授+傅佩芬教授:“行是知之始,知是行之成”-看新的研究结果如何指引临床治疗的选择

每年,乳腺癌领域会有大量的新研究数据出台,医生也会花大量的时间精力学习理解。但新的研究结果是否迅速地转化成了专业知识,这些新知识在临床实践上到底给予了医生怎样的价值和意义?

Eur Radiol:测量乳腺癌大小方面,哪种检查方法好呢,ABVS? US? MRI?

自动乳腺容积扫描(ABVS)就是三维立体的乳腺B超检查,与传统的二维乳腺B超检查相比,其能够直观地显示出肿瘤的位置、大小、形态等。目前被认为是一种最佳的、可以覆盖全乳腺组织的扫描技术,ABVS是检测和预防乳腺癌最有效的扫描工具。本研究旨在比较ABVS、超声(US)和MRI在测量乳腺癌大小及评价病变位置及声像特征与US的一致性,并将结果发表在Eur Radiol上。

Cancer Res:患有2型糖尿病的人患有癌症的风险也越高

在女性中,患有2型糖尿病的女性,患雌激素受体阴性乳腺癌的风险可能更高。

Baidu
map
Baidu
map
Baidu
map